DRP successfully predicts effect of 4 Breast Cancer drugs for Personalized Medicine
Hoersholm, Denmark, January 24th, 2017 – Oncology Venture Sweden AB (OV:ST) today announced that its Drug Response Predictor DRP™ tool in-licensed from Medical Prognosis Institute (MPI) for drug development was studied by MPI as a tool for Personalized Medicine – Patient Response Prediction – PRP™. MPI’s vision is to develop a tool in the form of a report over drugs that are most likely to be effective for the individual cancer patient. As a part of the strategy for carrying out this vision a study was set up in collaboration with Breast Cancer Experts at Danish oncology departments. The